Fisetin vs Luteolin
Both reach the senolytic shelf from different chemistry: a flavonol that topped the screen the whole idea came from, and a flavone that barely registered in it.
Short answer
Fisetin and luteolin are both graded preclinical / minimal, which leaves little or no controlled human data to choose between them. Fisetin is the one sold for senolytic use and anti-aging, while luteolin targets mast-cell stabilization, brain fog and neuroinflammation. Both are sold over the counter as supplements.
Fisetin
The most potent senolytic flavonoid in mice, with lifespan data — but the one human trial to report a clinical outcome (ROPE, knee osteoarthritis) was null; other senolytic-hypothesis trials remain unpublished.
Full Fisetin evidence reviewLuteolin
3',4',5,7-tetrahydroxyflavone, cynaroside
A genuinely strong mast-cell and microglial mechanism whose entire human record is combination products — and the one placebo-controlled test of luteolin alone was negative.
Full Luteolin evidence reviewFisetin vs Luteolin: head to head
- FDA status / approved use
Fisetin
Sold as a dietary supplement, not an approved drug; senolytic use is investigationalLuteolin
Sold as a dietary supplement; no FDA approval for any indication- Marketed for
Fisetin
Senolytic, anti-agingLuteolin
Mast-cell stabilization, brain fog / neuroinflammation, allergy, senolytic- Outcome areas
Fisetin
Cellular senescence; Longevity / lifespan; Joint / bone healthLuteolin
Immune function / inflammation; Cognitive function / memory; Cellular senescence- Evidence grade
Fisetin
Preclinical / minimalLuteolin
Preclinical / minimal- How it works
Fisetin
Senolytic: clears senescent 'zombie' cells, shown mainly in miceLuteolin
Inhibits mast-cell release of histamine and other mediators in lab studies- Route and dosing
Fisetin
Oral supplement, often taken in high intermittent dosesLuteolin
Oral capsule, typically 100–300 mg daily- Headline human result
Fisetin
No significant benefit for knee pain, function or cartilage at three months in the 2025 ROPE osteoarthritis RCTLuteolin
No benefit over placebo at either dose in a crossover screening trial of 21 Gulf War Illness veterans- Strongest evidence
Fisetin
Mouse senolytic, EBioMedicine 2018. Little or no controlled human outcome data for the marketed useFisetin evidence reviewPubMed 30279143Luteolin
Placebo-controlled crossover screen, IJERPH 2021. Little or no controlled human outcome data for the marketed useLuteolin evidence reviewPubMed 33802381- Key safety signal
Fisetin
Looks safe as a food compound; long-term safety of high senolytic doses is not establishedLuteolin
No long-term human safety data at supplement doses; inhibits CYP1A2 and CYP2C8 in lab studies- How it is obtained
Fisetin
Over the counter as a dietary supplementLuteolin
Over the counter as a dietary supplement
| Fisetin | Luteolin | |
|---|---|---|
| FDA status / approved use | Sold as a dietary supplement, not an approved drug; senolytic use is investigational | Sold as a dietary supplement; no FDA approval for any indication |
| Marketed for | Senolytic, anti-aging | Mast-cell stabilization, brain fog / neuroinflammation, allergy, senolytic |
| Outcome areas | Cellular senescence; Longevity / lifespan; Joint / bone health | Immune function / inflammation; Cognitive function / memory; Cellular senescence |
| Evidence grade | Preclinical / minimal | Preclinical / minimal |
| How it works | Senolytic: clears senescent 'zombie' cells, shown mainly in mice | Inhibits mast-cell release of histamine and other mediators in lab studies |
| Route and dosing | Oral supplement, often taken in high intermittent doses | Oral capsule, typically 100–300 mg daily |
| Headline human result | No significant benefit for knee pain, function or cartilage at three months in the 2025 ROPE osteoarthritis RCT | No benefit over placebo at either dose in a crossover screening trial of 21 Gulf War Illness veterans |
| Strongest evidence | Mouse senolytic, EBioMedicine 2018. Little or no controlled human outcome data for the marketed useFisetin evidence reviewPubMed 30279143 | Placebo-controlled crossover screen, IJERPH 2021. Little or no controlled human outcome data for the marketed useLuteolin evidence reviewPubMed 33802381 |
| Key safety signal | Looks safe as a food compound; long-term safety of high senolytic doses is not established | No long-term human safety data at supplement doses; inhibits CYP1A2 and CYP2C8 in lab studies |
| How it is obtained | Over the counter as a dietary supplement | Over the counter as a dietary supplement |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Preclinical / minimal:
- Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.
Our verdict
These are not interchangeable, and the senolytic case is clearly weaker for luteolin. Fisetin was the most potent senolytic of the ten flavonoids screened in the landmark study and extended both median and maximum lifespan in old mice, with an independent 2025 study finding reduced frailty and improved grip strength in aged but not young animals — while luteolin, a flavone rather than a flavonol, showed only weak activity in that same screen. Neither has a published human senolytic result: fisetin's trials are still ongoing with no outcomes reported, and luteolin has nothing in humans on that claim at all. Luteolin's genuine strength is elsewhere and it is mechanistic — in cultured human mast cells it out-performed cromolyn, the only licensed mast-cell blocker, on every mediator tested — but almost its entire human record is combination products, and the one published placebo-controlled test of luteolin on its own, a crossover in 21 Gulf War Illness veterans, was negative at both doses.
Fisetin fits if
Fisetin is the one to follow if the senolytic hypothesis is what interests you, on the clear understanding that every efficacy claim behind it is currently mouse data with the human trials still running.
Luteolin fits if
Luteolin is the one to read if your interest is mast cells, allergy or the microglial brain-fog story, treating the mechanism as a reason to watch the two completed trials of luteolin alone that have never reported results.
Fisetin vs Luteolin: common questions
- Is either fisetin or luteolin FDA-approved?
- No. Fisetin is sold as a dietary supplement, not an approved drug; senolytic use is investigational. Luteolin is sold as a dietary supplement; no FDA approval for any indication.
- Which has stronger human evidence, fisetin or luteolin?
- Neither. Both are graded preclinical / minimal, with little or no controlled human outcome data for the marketed use. The key source for fisetin is mouse senolytic, EBioMedicine 2018; for luteolin, it is placebo-controlled crossover screen, IJERPH 2021.
- What are the main safety concerns with fisetin and luteolin?
- Fisetin looks safe as a food compound; long-term safety of high senolytic doses is not established. Luteolin has no long-term human safety data at supplement doses; inhibits CYP1A2 and CYP2C8 in lab studies.
Key studies behind each
Fisetin
- Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. (2018). Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. PubMed 30279143
- Murray KO, Mahoney SA, Ludwig KR, et al. (2025). Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging. Aging Cell. PubMed 40437670
- Silva M, Wacker DA, Driver BE, et al. (2024). Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients: Study protocol for a multi-center, randomized, adaptive allocation clinical trial. Trials. PubMed 39434114
- Ji J, Crespi CM, Yee L, et al. (2026). A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design. Ther Adv Med Oncol. PubMed 41835341
Luteolin
- Shi M, Chen Z, Gong H, Peng Z, Sun Q, Luo K, Wu B, Wen C, Lin W. (2024). Luteolin, a flavone ingredient: Anticancer mechanisms, combined medication strategy, pharmacokinetics, clinical trials, and pharmaceutical researches. Phytother Res. PubMed 38088265
- Sampson L, Rimm E, Hollman PC, de Vries JH, Katan MB. (2002). Flavonol and flavone intakes in US health professionals. J Am Diet Assoc. PubMed 12396158
- Shimoi K, Okada H, Furugori M, Goda T, Takase S, Suzuki M, Hara Y, Yamamoto H, Kinae N. (1998). Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Lett. PubMed 9827549
- Tsilioni I, Theoharides TC. (2024). Luteolin Is More Potent than Cromolyn in Their Ability to Inhibit Mediator Release from Cultured Human Mast Cells. Int Arch Allergy Immunol. PubMed 38588651
The full evidence reviews
- Fisetin: a powerful senolytic in mice, unproven in humans
A dietary flavonoid that's the most potent senolytic of its class and extends lifespan in mice — but the human trials that would test the senolytic claim are still ongoing, with no published outcomes.
Updated August 2026
- Luteolin: an excellent mechanism, and almost no human evidence
Luteolin beats the only licensed mast-cell blocker in a dish and calms microglia in aged mice — but nearly every human trial gave people a combination product, and the one placebo-controlled test of luteolin alone was negative.
Updated August 2026